ArticleJournal of radiation research2026
Predictors of acute genitourinary toxicity in real-time image-gated spot-scanning proton beam therapy for prostate cancer.
Article in Journal of radiation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Proton beam therapy (PBT) provides sharper dose gradients than conventional photon radiotherapy, potentially reducing radiation exposure to normal tissues. However, acute genitourinary adverse events (GU AEs) remain a clinical concern. This study aimed to evaluate the incidence and predictors of grade ≥ 2 acute GU AEs in patients with localized prostate cancer treated with real-time image-gated, spot-scanning PBT (RGPT). We analyzed the prospective study data of 326 patients who received RGPT at a dose of 63 Gy (relative biological effectiveness [RBE]) in 21 fractions between 2019 and 2021. Acute GU AEs were graded according to the Common Terminology Criteria for Adverse Events (version 5.0). Multivariable logistic regression was used to analyze potential predictive factors, including baseline International Prostate Symptom Score (IPSS), age, comorbidities, hydrogel spacer placement, use of anticoagulants or urinary symptom medications, clinical stage, National Comprehensive Cancer Network (NCCN) risk classification, prostate volume, and dose-volume histogram parameters. Grade 2 acute GU AEs occurred in 127 patients (39.0%), whereas no grade ≥ 3 events were observed. Moderate (odds ratio [OR] = 1.71; 95% confidence interval [CI]: 1.03-2.82) and severe (OR = 3.75; 95% CI: 1.49-9.46) baseline IPSS, as well as age ≥ 75 years (OR = 1.80; 95% CI: 1.10-2.95), were significant independent predictors of grade ≥ 2 GU AEs. No dose-volume histogram parameters were significantly associated with grade ≥ 2 GU AEs. Baseline urinary symptoms and older age were independent predictors of grade ≥ 2 GU AEs, emphasizing the importance of pretreatment evaluation in optimizing patient selection and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.